FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations

Murakami, Koji

doi:10.5306/wjco.v2.i5.229

Cited by 30 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current literature includes relatively little data regarding the diagnostic role of PET/CT in patients with periampullary tumors (16)(17)(18)(19). Although the FDG-sensitivity of tumors originating from the pancreas has been reported to be between 88% and 92% (17,(19)(20)(21)(22)(23)(24)(25), there are limited findings for tumors that originate from the ampulla or distal choledochus (16)(17)(18).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have reported the clinical utility of CA 19-9 levels and PET/CT in the diagnosis and management of periampullary tumors (14)(15)(16)(17)(18)(19). Although results from these studies have been encouraging, data regarding the link between CA 19-9 levels, SUV max , and confirmed histopathological features are lacking in the current literature on periampullary tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

18F-FDG activitiy PET/CT and CA-19.9 levels for the prediction of histopathological features and localization of peri- ampullary tumors

Akçam

Ülkü²,

Rencüzoğulları³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: We sought to investigate the roles of maximum standardized uptake value (SUV max ) and serum carbohydrate antigen in predicting the histopathological features of periampullary tumors. Materials and Methods: Thirty-four patients with histologically confirmed periampullary tumors were classified into two groups, according to the localizations of their tumors (ampulla Vateri or pancreas). SUV max was obtained from [(18)F]-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT). SUV max and CA 19-9 levels were measured and compared with histopathological features of the tumors. Logistic regression was used to assess the significance and independence of predictive factors. Results: 18F-FDG PET/CT SUV max (<2.5 vs. ≥2.5; p=0.031) and CA 19-9 level (normal vs. elevated; p=0.045) were significantly and independently predictive of the histopathological origin of the tumors (ampulla Vateri vs. pancreas). The ratio of CA 19-9 levels and SUV max were found to be higher in cases of poorly differentiated tumors and tumors greater than 2 cm in diameter. Conclusion: A surgical approach to treatment may be considered for patients who have both i) an established or suspected diagnosis of periampullary tumors and ii) low SUV max and CA 19-9 levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

18F-FDG activitiy PET/CT and CA-19.9 levels for the prediction of histopathological features and localization of peri- ampullary tumors

Akçam

Ülkü²,

Rencüzoğulları³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…18 F]fluorodeoxyglucose ( 18 FDG PET) has become a useful tool in the evaluation of tumor lesions, particularly for pancreatic cancer, and the discovery of distant metastases [40][41][42][43]. 18 FDG is a glucose analog that is taken up aggressively by rapidly growing malignant masses, but not all hot spots are cancerous.…”

Section: Discussionmentioning

confidence: 99%

Three Dimensional Projection Environment for Molecular Design and Surgical Simulation

Wickstrom

Chen²,

Devadhas³

et al. 2011

View full text Add to dashboard Cite

REPORT DOCUMENTATION PAGEForm Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. (From -To) 29- 07-2009 -28-07-2011 REPORT DATE (DD-MM-YYYY) 28-08-2011 REPORT TYPE Final DATES COVERED SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)Medical Research and Materiel USAMRMC Materiel Command TATRC Telemedicine & Advanced Fort Detrick SPONSOR/MONITOR'S REPORTTechnology Research Center Maryland 21702-5012 NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for public release; distribution unlimited SUPPLEMENTARY NOTES ABSTRACTWe hypothesized in Aim 1 that docking of three-dimensional (3D) projections of potential target binding agents with 3D projections of macromolecular disease targets visualized on a computer with touch and feel feedback will enable identification of optimal agent designs, and culling of suboptimal agent designs, prior to synthesis. We found that direct measurements of cellular uptake of two different EGF fragments, EGF20-31 and EGF32-48, agreed with the computer predictions of no uptake by EGF20-31, and significant uptake by EGF32-48. This observation is consistent with our first hypothesis. We hypothesized in Aim 2 that 3D FDG PET images of patients superimposed on 3D anatomical images of patients visualized on a large computer display would enable improved preoperative planning, because the FDG PET images revealed specific sites of active disease. We found that a set of 6 experienced surgeons found that the final 3D version was accurate, useful, and worth applying in practice. This observation is consistent with our second hypothesis. SUBJECT TERMScancer, computerized tomography, haptic, hybridization, imaging, molecular dynamics, nuclear medicine, oncogene, pancreatic, positron emission tomography, receptors, surgery, volumetric A. INTRODUCTIONWe hypothesized that our fusion of genetic, visual, and tactile information would improve surgeons' understanding of the extent of disease and will ultimately permit surgeons to better plan operations and to prepare for the actual pathology found. We proposed to combine current medical imaging technologies with genetic imaging to leverage our ability to pr...

show abstract

“…The role of positron emission tomography scanning (PET) is still unclear in pancreatic cancer. Chronic pancreatitis is very difficult to differentiate from pancreatic cancer and in turn it has a low specificity for detecting pancreatic cancer [35].…”

Section: Screening Toolsmentioning

confidence: 99%

Pancreatic Cancer Screening: Attempts and Possibilities

Mourad¹,

Evans²,

Aly³

et al. 2017

J Hepatol Gastroint Dis

View full text Add to dashboard Cite

Pancreatic cancer has one of the highest disease specific mortality of any malignancy, despite significant advances in diagnosis and treatment over the past decade. Currently there are no efficient screening tools available that can be recommended outside a high-risk population. Screening of high-risk populations has been suggested for early detection of curable pancreatic cancer to improve outcome. There is still however, a lack of an ideal screening method. Efficient and reliable screening methods to achieve early detection of pancreatic cancer are therefore required.

show abstract

FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations

Cited by 30 publications

References 16 publications

18F-FDG activitiy PET/CT and CA-19.9 levels for the prediction of histopathological features and localization of peri- ampullary tumors

18F-FDG activitiy PET/CT and CA-19.9 levels for the prediction of histopathological features and localization of peri- ampullary tumors

Three Dimensional Projection Environment for Molecular Design and Surgical Simulation

Pancreatic Cancer Screening: Attempts and Possibilities

Contact Info

Product

Resources

About